New patents on mucosal delivery of vaccines

Bibliography

• Davis SS. Nasal vaccines. Adv Drug Del Rev 2001;51:21-42
   PubMed Web of Science ®Google Scholar
• Nugent J, Po AL, Scott EM. Design and delivery of non-parenteral vaccines. J Clin Pharm Ther 1998;23(4):257-85
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-58
   PubMed Web of Science ®Google Scholar
• Ryan EJ, Daly LM, Mills KHG. Immunomodulators and delivery systems for vaccination by mucosal routes. TRENDS in Biotech 2001;19(8):293-304
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003;21:89-95
   PubMed Web of Science ®Google Scholar
• Magistris MTD. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Del Rev 2006;58:52-67
   PubMed Web of Science ®Google Scholar
• McGhee JR, Lamm ME, Strober W. Mucosal immune responses: an overview. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editor, Mucosal immunology, 2nd edition. Academic Press, New York, 1999;485-506
   Google Scholar
• Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14:430-45
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Halstensen TS, Kett K, et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989;97:1562-84
   PubMed Web of Science ®Google Scholar
• Sminia T, Kraal G. Nasal-associated lymphoid tissue. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editor, Mucosal Immunology, 2nd edition. Academic Press, New York, NY 1999;357-79
   Google Scholar
• Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: Implications for future treatment, J Allergy Clin Immunol 2008;121(6):1344-50
   PubMed Web of Science ®Google Scholar
• Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252(5480):252
   PubMed Web of Science ®Google Scholar
• Jeurissen SHM, Claassen HJHM, Kraal G. Use of liposomes containing a chelating agent, a fungicide or a secropine for improving mucosal vaccination. WO1998040062; 1998
   Google Scholar
• Thibodeau L, Lavallee C. Use of HIV-1 gp120 and gp160 proteins modified in the v3 loop for the preparation of vaccine compositions and formulations containing the same. US20067063849; 2006
   Google Scholar
• Venkatesan N, Vyas SP. Polysaccharide coated liposomes for oral immunization: development and characterization. Int J Pharm 2000;203:169-77
   PubMed Web of Science ®Google Scholar
• Langer RS. Oral delivery of vaccines using polymerized liposomes. US19985762904; 1998
   Google Scholar
• Ford MJ. Fusogenic liposomes that is free of active neuraminidase. US19995985318; 1999
   Google Scholar
• Patel GB, Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2005;2:407-21
   PubMedGoogle Scholar
• Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 1999;19:317-57
   PubMed Web of Science ®Google Scholar
• Sprott GD, Patel GB, Choquet CG, Ekiel I. Formation of stable liposomes from lipid extracts of archaeobacteria (archaea). WO1993008202; 1993
   Google Scholar
• Sprott GD, Patel GB, Makabi-Panzu B, Tolson DL. Archaeosomes containing coenzyme Q10 and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles. US20006132789; 2000
   Google Scholar
• Papahadjopoulos PD. Large unilamellar vesicles (LUV) and method of preparing same. US19784078052; 1978
   Google Scholar
• Unger EC. Method for delivering bioactive agents using cochleates. US20026403056; 2002
   Google Scholar
• Mannino RJ, Fogerite SG. Reconstituting viral glycoproteins into large phospholipid vesicles. US19894871488; 1989
   Google Scholar
• Margolis D, Gould-Fogerite S, Mannino RJ. Integrative protein-DNA cochleate formulations and methods for transforming cells. US20026340591; 2002
   Google Scholar
• Gould-Fogerite S, Mannino RJ. Protein or peptide cochleate vaccines and methods of immunizing using the same. US19975643574; 1997
   Google Scholar
• Okamoto T, Kaneda Y, Yuzuki D, et al. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther 1997;4:969-76
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Locht C, Riveau G, et al. Bordetella strain expressing the FHA hybrid, liposomes and vaccines US20036660261; 2003
   Google Scholar
• Gluck R, Mischler R. Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine. US19965565203; 1996
   Google Scholar
• Pluschke G, Markus M, Robinson J, et al. Compositions and methods for the generation of protective immune responses against malaria. US20077198791; 2007
   Google Scholar
• Cox JC, Sjölander A, Barr IG. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998;32(3):247-71
   PubMed Web of Science ®Google Scholar
• Morein B, Hub KF, Abusugra I. Current status and potential application of ISCOMs in veterinary medicine. Adv Drug Del Rev 2004;56(10):1367-82
   PubMed Web of Science ®Google Scholar
• Hub KF, Lövgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001;51(1-3):149-59
   PubMed Web of Science ®Google Scholar
• Morein B, Lovgren BK, Ekstr MJ. ISCOM OR ISCOM-MATRIX comprising a mucus targetting substance and optionally, an antigen. CA19972247522; 1997
   Google Scholar
• Ghazi HO, Potter CW, Smith TL, Jennings R. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. J Med Microbiol 1995;42(1):53-61
   PubMed Web of Science ®Google Scholar
• Morein B, Lövgren BK. Composition comprising ISCOM particles and live microorganisms. WO2004084941; 2004
   Google Scholar
• Andrianov AK, Payne LG. Polymeric carriers for oral uptake of microparticulates. Adv Drug Del Rev 1998;34:155-70
   PubMed Web of Science ®Google Scholar
• Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 2006;24(19):4201-11
   PubMed Web of Science ®Google Scholar
• Gupta PN, Mahor S, Rawat A, et al. Lectin anchored stabilized biodegradable nanoparticles for oral immunization: Development and in vitro evaluation. Int J Pharm 2006;318:163-73
   PubMed Web of Science ®Google Scholar
• O'Hagan D, Singh M, Ott G. Microparticles with adsorbent surfaces methods of making same and uses thereof. US20056884435; 2005
   Google Scholar
• Dea-Ayuela MA, Rama-Iniguez S, Torrado-Santiago S, Bolas-Fernandez F. Microcapsules formulated in the enteric coating copolymer Eudragit L100 as delivery systems for oral vaccination against infections by gastrointestinal nematode parasites. J Drug Target 2006;4:567-75
   Google Scholar
• Tafaghodi M, Sajadi TSA, Jaafari MR. Formulation, characterization and release studies of alginate microspheres encapsulated with tetanus toxoid. J Biomater Sci Polym Ed 2006;17(8):909-24
   PubMed Web of Science ®Google Scholar
• Sturesson C, Degling WL. Comparison of poly (acryl starch) and poly (lactide-co-glycolide) microspheres as drug delivery system for a rotavirus vaccine. J Control Rel 2000;68:441-50
   PubMed Web of Science ®Google Scholar
• Haining WN, Anderson DG, Little SR, et al. pH-triggered microparticles for peptide vaccination. J Immunol 2004;173:2578-85
   PubMed Web of Science ®Google Scholar
• Stanley AC, Buxton D, Innes EA, Huntley JF. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 2004;22(29-30):3929-41
   PubMed Web of Science ®Google Scholar
• Kim SY, Doh HJ, Ahn JS, et al. Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly (D,L-lactide-co-glycolide) microparticles. Vaccine 1999;17(6):607-16
   PubMed Web of Science ®Google Scholar
• Allaoui-Attarki K, Pecquet S, Fattal E, et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun 1997;65(3):853-7
   PubMed Web of Science ®Google Scholar
• Burnett PR, Van Hamont JE, Reid RH, et al. Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres. US19985762965; 1998
   Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Rel 2004;100:5-28
   PubMed Web of Science ®Google Scholar
• Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1998;1:246-53
   Google Scholar
• Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005;57(3):411-30
   PubMed Web of Science ®Google Scholar
• Illum L, Chatfield SN. Vaccine compositions including chitosan for intranasal administration and use thereof. US20026391318; 2002
   Google Scholar
• Illum L, Chatfield SN, Roberts M. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000;68:5764-70
   PubMed Web of Science ®Google Scholar
• Davis SS, Lin W, Bignotti F, Ferruti P. Conjugate of polyethylene glycol and chitosan. US20046730735; 2004
   Google Scholar
• Watts PJ, Illum L. Pharmaceutical compositions of chitosan with type-A gelatin. US20026465626; 2002
   Google Scholar
• Gombotz WR, Mumper RJ, Hoffman AS, Bouchard LS. Methods and compositions for the oral delivery of therapeutic agents. US19955451411; 1995
   Google Scholar
• Goosen MFA, O'Shea GM, Sun AMF. Microencapsulation of living tissue and cells. US19894806355; 1989
   Google Scholar
• Bowersock TL, Park K, Porter RE. Alginate-based vaccine compositions. US19975674495; 1997
   Google Scholar
• Gerber JD. Adjuvant composition for mucosal and injection delivered vaccines. US20046676958; 2004
   Google Scholar
• See JR, See DM. Method for inducing a systemic immune response to an antigen. US20006015576; 2000
   Google Scholar
• Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 1999;236:215-36
   PubMed Web of Science ®Google Scholar
• Mcghee JR, Yamamoto S, Takeda Y, Kiyono H. Use of cholera toxin mutants as mucosal adjuvant. WO1998045324; 1998
   Google Scholar
• Briles DE, Wu HY. Mucosal administration of pneumococcal antigens. US20006027734; 2000
   Google Scholar
• Rappuoli R, Pizza M. Mucosal DTPa vaccines. US20077279169; 2007
   Google Scholar
• Cornelissen CN, Price G, Russell M, Connell T. chimerac tbp-toxin proteins as mucosal adjuvants for vaccination against neisseriae. WO2007/002018; 2007
   Google Scholar
• Lycke N. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol Lett 2005;97:193-8
   PubMed Web of Science ®Google Scholar
• Podda SPA, Giudice GD, Ruggiero P, et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003;2(2):285-93
   PubMedGoogle Scholar
• Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988;6(3):269-77
   PubMed Web of Science ®Google Scholar
• Agsteribbe ED, deHaan L, van Scharrenburg GJM, Wilschut JC. Vaccines with an LTB adjuvant. EP1071456; 2003
   Google Scholar
• Crane TR. Aqueous immunologic adjuvant compostions of monophosphoryl lipid A US20026491919; 2002
   Google Scholar
• Helting TB. Atoxic, immunogenic product of tetanus toxin. US19804200627; 1980
   Google Scholar
• Roberts M, Dougan G. Vaccine compositions for mucosal delivery. WO1993021950; 1993
   Google Scholar
• McCluskie MJ, Davis HL. CpG DNA as mucosal adjuvant, Vaccine 2000;18:231-7
   Web of Science ®Google Scholar
• Asahi-Ozaki Y, Itamura S, Ichinohe T, et al. Microbes Infect 2006;8:2706-14
   PubMed Web of Science ®Google Scholar
• Roland KL, Tinge SA, Killeen KP, Kochi SK. Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther 2005;7(1):62-72
   PubMedGoogle Scholar
• Daudel D, Weidinger G, Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 2007;6(1):97-110
   PubMed Web of Science ®Google Scholar
• Lewis GK. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet. Expert Rev Vaccines 2007;6(3):431-40
   PubMed Web of Science ®Google Scholar
• Kleanthous H, Londono-Arcila P, Freeman D. Use of salmonella vectors for vaccination against hellicobacter infection. WO2001032014; 2001
   Google Scholar
• Aldovini A, Young RA. Recombinant mycobacterial vaccines. US19985830475; 1998
   Google Scholar
• Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007;6(2):255-66
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005;18(2):283-91
   PubMed Web of Science ®Google Scholar
• Zhang WW. Adenoviral vectors: development and application. Expert Opin Investig Drugs 1997;6(10):1419-57
   PubMedGoogle Scholar
• Bae YS, Jung HR. Replication-competent recombinant Sabin type 1 strain of poliovirus. US20046696289; 2004
   Google Scholar
• Arnold EV, Arnold GF. Chimeric rhinoviruses. US19985714374; 1998
   Google Scholar
• Small PA Jr, Bender BS, Meitin CA, Moss B. Live recombinant vaccine comprising inefficiently or non-replicating virus WO1999007869; 1999
   Google Scholar
• Malone RW, Malone JG. DNA vaccines for eliciting a mucosal immune response. US20006110898; 2000
   Google Scholar
• Roy K, Huang SK, Sampson H, Leong KW. Oral delivery of nucleic acid vaccines by particulate complexes. US20026475995; 2002
   Google Scholar
• Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G. Liposome (Lipodine)-mediated DNA vaccination by the oral route. J Liposome Res 2002;12(1-2):185-97
   PubMed Web of Science ®Google Scholar
• Sloat BR, Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 2006;23(2):262-9
   PubMed Web of Science ®Google Scholar
• Artursson P, Christensen BE, Koping-Hoggard M, Varum KM, Tommeraas K. Non-viral gene delivery system. US20050164964; 2005
   Google Scholar
• Mohapatra SS, Kumar M, Huang SK, Leong K. Gene expression vaccine US20067118888; 2006
   Google Scholar
• Arntzen CJ, Mason HS, Haq TA. Oral immunization with transgenic plants. US20016194560; 2001
   Google Scholar
• Sohn U, Nam HG, Park DH, Kim KH. Recombinant human papillomavirus vaccine expressed in transgenic plants, US Patent 6444805; 2002
   Google Scholar
• Arntzen CJ, Lam DMK. Vaccines expressed in plants US20015914123; 2001
   Google Scholar
• Koprowski H, Yusibov V, Hooper DC, Modelska A. Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins, US 6042832; 2000
   Google Scholar
• Yang ZQ, Liu QQ, Pan ZM, et al. Expression of the fusion glycoprotein of newcasstle disease virus in transgenic rice and its immunogenicity in mice, Vaccine 2007;25:591-8
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products. Note for guidance on preclinical pharmacological and toxicological testing of vaccines. London, CPMP, 1998 (document CPMP/SWP/465/95)
   Google Scholar
• Sesardic D. Regulatory considerations on new adjuvants and delivery systems Vaccine 24S2 2006; S2/86-S2/87
   Google Scholar
• Aguilar JC, RodrIguez EG. Vaccine adjuvants revisited, Vaccine 2007;25:3752-62
   PubMed Web of Science ®Google Scholar